Profund Advisors’s Sutro Biopharma STRO Stock Holding History

Profund Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,025	Closed	-$186K	–	1133
2023 Q1	$186K	Buy	+4,025	New	+$255K	0.01%	1017

Other funds holding STRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Profund Advisors's STRO Position: Q2 2023 in Review

Profund Advisors sold out of Sutro Biopharma (STRO) in Q2 2023, closing a stake of 4,025 shares — an estimated $186K sold.

Profund Advisors first reported a position in STRO in Q1 2023 and held it in 1 quarter. The position peaked at $186K in Q1 2023. 120 funds tracked by Wall St. Rank hold STRO as of Q2 2023.

Profund Advisors reported no remaining Sutro Biopharma position as of Q2 2023 after selling out during the quarter.
Profund Advisors sold 4,025 Sutro Biopharma shares in Q2 2023, an estimated $186K.
Profund Advisors first reported a position in Sutro Biopharma in Q1 2023 and held it in 1 quarter.
Profund Advisors's Sutro Biopharma position peaked at $186K in Q1 2023.
120 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2023.

Based on Profund Advisors's 13F filing for Q2 2023, filed 10 Aug 2023.